TLDR
- CRISPR Therapeutics saw ARK Invest acquire 112,815 shares valued at approximately $5.63M via ARKK and ARKG funds
- PayPay Corp received a 275,000-share investment totaling roughly $4.4M through ARK’s fintech-focused ETF
- Additional investments included GeneDx (approximately $4.43M) and Tempus AI (around $991K)
- ARK divested from Teradyne (roughly $3.3M) and Ionis Pharmaceuticals (about $3.26M)
- Holdings in 10x Genomics and Circle Internet Group were also scaled back
Cathie Wood’s ARK Invest deployed more than $10 million in capital across multiple purchases on March 12, 2026, while simultaneously reducing several holdings, based on the investment firm’s public trade documentation.
The most significant acquisition was in CRISPR Therapeutics, with ARK accumulating 112,815 shares distributed between the ARK Innovation ETF and ARK Genomic Revolution ETF. The combined investment totaled approximately $5.63 million.
As a leading gene-editing biotechnology firm, CRISPR Therapeutics represents ARK’s ongoing commitment to the genomic medicine sector and its transformative potential.
The investment firm’s second-largest transaction involved PayPay Corp, a digital payments platform. ARK accumulated 275,000 shares via the ARK Fintech Innovation ETF, representing an investment of approximately $4.4 million.
PayPay Corp experienced a notable 13.50% gain during the trading session. This acquisition reinforces ARK’s strategic emphasis on digital payment infrastructure and fintech innovation.
Two additional companies received capital allocations from ARK. The firm purchased 52,075 shares of GeneDx, which specializes in genomic diagnostics, for roughly $4.43 million. Additionally, 18,820 shares of Tempus AI, which operates in the AI-powered healthcare data space, were acquired for approximately $991,000.
Where ARK Pulled Back
Regarding divestitures, ARK liquidated 10,919 shares of Teradyne, which manufactures semiconductor testing equipment, through the ARK Innovation ETF. The transaction value approached $3.3 million. Teradyne experienced a 5.09% decline during the session.
This divestiture represents a continuation of ARK’s strategy to systematically reduce its Teradyne exposure across multiple trading days.
The firm also liquidated 43,533 shares of Ionis Pharmaceuticals via the ARKG ETF, valued at roughly $3.26 million. Ionis shares declined 3.28% during the trading day.
The Ionis transaction extends ARK’s ongoing reduction in exposure to the RNA therapeutics developer.
Two additional positions experienced reductions. ARK sold 18,392 shares of 10x Genomics, which develops gene expression analysis technologies, for approximately $376,000 across both ARKK and ARKG portfolios.
Circle Internet Group, a blockchain payments and stablecoin operator, saw ARK divest 11,194 shares through ARKK for roughly $1.26 million.
What Analysts Say
Wall Street analysts currently assign “Strong Buy” ratings to both GeneDx and Ionis Pharmaceuticals. Among these stocks, GeneDx shows the most substantial upside opportunity, with projections indicating approximately 100% potential appreciation.
CRISPR Therapeutics, Tempus AI, Teradyne, and 10x Genomics each receive “Moderate Buy” consensus ratings from the analyst community. PayPay Corp holds a “Hold” rating.
ARK also executed a minor transaction, purchasing 54,736 shares of Canton Strategic Holdings through the ARKF ETF, with a valuation of approximately $254,522.
